Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough to acquire NeoGenesis assets
Financial terms of the deal, which is subject to normal closing conditions, have not been disclosed by the companies, but the acquisition is expected to close later in
Financial terms of the deal, which is subject to normal closing conditions, have not been disclosed by the companies, but the acquisition is expected to close later in
This investigational new drug (IND) allowance moves Manhattan forward into the next stage of Oleoyl estrone (OE)’s development and was granted on the preclinical chemistry, manufacturing, and safety
Data from preclinical studies indicate that the combination vaccine elicited protective immune responses to respiratory syncytial virus (RSV) and parainfluenza virus type-3 (PIV-3), two leading causes of pediatric
The small business innovation research (SBIR) grant supports research to optimize a human protein to enhance its ability to inhibit formation of new blood vessels, which may provide
As part of the ongoing review of COX-2 inhibitors, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) held hearings with Pfizer for Onsenal, Dynastat
Worldwide sales of Celebrex topped $3.3 billion and Bextra sales totaled nearly $1.3 billion in 2004. Pfizer’s Lipitor also delivered strong double-digit revenue growth, becoming the world’s first
Novartis’ net sales rose 14% to $28.2 billion, with strong results being recorded in both pharmaceuticals and consumer health, where the company’s OTC and medical nutrition operations offset
The vaccine candidate will be manufactured using GenVec’s proprietary adenovector technology and 293-ORF6 cell line based manufacturing process. The vaccine is based on two antigens and is designed
This open-label, non-randomized study will seek to enroll patients who have received one prior chemotherapy regimen and may or may not have received an EGFR Kinase inhibitor to
The phase II proof of principle study is to evaluate Phytompharm’s PYM50028 (Cogane), an orally active, synthetic, neuroprotective and neuroregenerative product under development as a treatment for Alzheimer’s